Grubb M F, Diamond S, Christ D D
Drug Metabolism and Pharmacokinetics Section, The DuPont Merck Pharmaceutical Company, Newark, DE 19714, USA.
Drug Metab Dispos. 1997 Dec;25(12):1424-8.
The human immunodeficiency virus-1 protease inhibitor SD894 was evaluated as an inhibitor and inducer of cytochromes P450 (CYPs) in rats. After addition of 10 microM SD894 and 2 mM NADPH to liver microsomes from dexamethasone-treated rats, a type II spectrum appeared. Within 2 min, it was replaced by a type III spectrum, with absorbance maxima at 426 and 456 nm, similar to those observed with alkylamines (SKF-525A) and arylamines (p-chloroaniline). Preincubation of microsomes from dexamethasone-treated rats with SD894 and NADPH resulted in a time-dependent inhibition of testosterone 6beta-hydroxylation (CYP 3A1/2 activity), which was decreased to 25% of controls after 30 min. Testosterone 16beta-hydroxylation (CYP 2B1/2 activity) was unaffected under these conditions. Testosterone 6beta-hydroxylation rates in liver microsomes from pregnenolone 16alpha-carbonitrile-treated rats incubated with 10 microM SD894 and NADPH, washed, and reisolated by ultracentrifugation were reduced by 71%, whereas 16beta-hydroxylation was unaffected by SD894. Immunoblots of liver microsomes from rats dosed iv with SD894 or ip with TAO displayed increased CYP 2B1 and CYP 3A1 levels, respectively. Testosterone 6beta-hydroxylase activity in microsomes from TAO-treated rats was greater than controls. Preincubation of these microsomes with potassium ferricyanide produced an additional 50% increase, consistent with disruption of a metabolite-CYP complex. Microsomes from SD894-treated rats displayed a 3-fold increase in testosterone 16beta-hydroxylation. Potassium ferricyanide preincubation did not increase activity. Thus, although SD894 appears to inhibit CYP in vitro in a manner typical of other amine-containing, mechanism-based inhibitors, in vivo induction by 10 mg/kg daily doses of SD894 affects a different isozyme than does inhibition. The mechanism of induction is unknown.
人类免疫缺陷病毒1型蛋白酶抑制剂SD894在大鼠体内被评估为细胞色素P450(CYPs)的抑制剂和诱导剂。向地塞米松处理的大鼠肝脏微粒体中加入10微摩尔SD894和2毫摩尔烟酰胺腺嘌呤二核苷酸磷酸(NADPH)后,出现了II型光谱。在2分钟内,它被III型光谱取代,在426和456纳米处有最大吸光度,类似于用烷基胺(SKF - 525A)和芳基胺(对氯苯胺)观察到的情况。用地塞米松处理的大鼠微粒体与SD894和NADPH预孵育导致睾酮6β - 羟基化(CYP 3A1/2活性)呈时间依赖性抑制,30分钟后降至对照的25%。在这些条件下,睾酮16β - 羟基化(CYP 2B1/2活性)未受影响。用10微摩尔SD894和NADPH孵育、洗涤并通过超速离心重新分离的孕烯醇酮16α - 腈处理的大鼠肝脏微粒体中的睾酮6β - 羟基化速率降低了71%,而16β - 羟基化不受SD894影响。静脉注射SD894或腹腔注射TAO的大鼠肝脏微粒体免疫印迹分别显示CYP 2B1和CYP 3A1水平升高。TAO处理的大鼠微粒体中的睾酮6β - 羟化酶活性高于对照。用铁氰化钾对这些微粒体进行预孵育使活性额外增加50%,这与代谢物 - CYP复合物的破坏一致。SD894处理的大鼠微粒体中的睾酮16β - 羟基化增加了3倍。铁氰化钾预孵育未增加活性。因此,尽管SD894在体外似乎以其他含胺的基于机制的抑制剂的典型方式抑制CYP,但每日10毫克/千克剂量的SD894在体内诱导所影响的同工酶与抑制作用不同。诱导机制尚不清楚。